Varian Medical Systems updated logoVarian Medical Systems (NYSE:VAR) today announced a trio of personnel changes including the appointment of a new president and COO.

Effective Oct. 5, 2020, current Varian Oncology Systems president Chris Toth will take over the newly created roll of president and COO. As a result, current senior VP of global operations Kevin O’Reilly will take over as president of Varian Oncology Systems and VP of revenue operations Stephanie Foster will become senior VP of global supply chain operations.

“This announcement is a testament to the deep and diverse bench of talented leaders we have at Varian, as well as a reflection of our commitment to realizing our vision and strengthening our support for Varian’s customers and their patients,” Varian CEO Dow Wilson said in a news release. “I’m thrilled to congratulate Chris, Kevin and Stephanie on their expanded leadership roles, and I’m confident that they will ensure our entire team is well-positioned to build on Varian’s success and accomplish our goals for 2021 and beyond.”

A nearly 20-year veteran in the industry, Toth joined Varian in 2001 and worked his way through multiple executive positions before taking over as president of Varian Oncology Systems. His new roles include the responsibility of overseeing Varian’s business operations as he reports to Wilson.

O’Reilly joined Varian in 2009, having traversed multiple industries and geographies before landing at the cancer care technology developer, previously serving as Varian’s president of the Asia Pacific region. Foster, who joined Varian just last year, has 30 years of experience in supply chain, operations and manufacturing in multiple regulated industries.


“This is an important moment in Varian’s history, and I am honored to work with our talented and agile team to build on our strong momentum,” Toth said. “Varian is moving at full speed to achieve our goal of a world without fear of cancer. While we work toward completing a transformational combination with Siemens Healthineers, we’re continuing to make impressive progress on our efforts to provide more intelligent solutions, data and insights to deliver world-class cancer care globally.

“Looking ahead, we don’t intend to slow down. Our unwavering focus on helping our customers care for their patients will continue to propel us forward.”